Journal: bioRxiv

Article Title: Functional and sensitivity profiling of the KIT Mutation Landscape in Melanoma

doi: 10.64898/2026.02.18.706482

Figure Lengend Snippet: KIT mutations shows differential responses towards common KIT inhibitors in vitro. (A) Western Blot analysis revealed changes in cell growth and proliferation pathways upon expression of KIT mutants in MeWO melanoma cells. (B) Upper panel: Monitoring relative growth of melanoma cell spheroids expressing KIT mutants using high-content microscopy. Lower panel: Representative image depicting spheroid size after 8 days of growth in 3D environment. (C) Western Blot demonstrating the expression of KIT in Ba/F3 cells. (D) Assessment of relative growth of Ba/F3 cells expressing different KIT mutants following withdrawal of IL-3 from the culture medium, measured using cell-titre glo assay. (E) Heatmap shows the relative IC50 of Ba/F3 cell with KIT mutants against KIT inhibitors. (F) Violin plot illustrating the IC50 values of MeWo cells expressing KIT mutants when treated with various KIT inhibitors. Results were obtained from three independent experiments. The horizontal line represents the mean, and statistical analysis was performed using one-way ANOVA.

Article Snippet: Small molecule inhibitors (Imatinib, Sunitinib, Nilotinib, Nintedanib, and Ripretinib) were purchased from MedChemExpress, dissolved in DMSO to a 10 mM stock, and stored at −80°C.

Techniques: In Vitro, Western Blot, Expressing, Microscopy, Glo Assay

Journal: bioRxiv

Article Title: Functional and sensitivity profiling of the KIT Mutation Landscape in Melanoma

doi: 10.64898/2026.02.18.706482

Figure Lengend Snippet: In vivo anti-tumor efficacy of KIT inhibitors against MeWo cells expressing KIT WT/mutants in a mouse xenograft model. (A-C) Response of MeWO-KIT-WT, MeWo-KIT p.L576P, and MeWo-KIT-p.N822K mouse xenograft models to Imatinib, Sunitinib, Nilotinib, and Nintedanib, respectively (n = 3 independent experiments). (D-F) Response of MeWO-KIT-WT, MeWo-KIT p.L576P, and MeWo-KIT-p.N822K mouse xenograft models to Ripretinib (n = 3 independent experiments). Fraction of tumor growth represents the change in tumor volume normalized to day 0 of treatment.

Article Snippet: Small molecule inhibitors (Imatinib, Sunitinib, Nilotinib, Nintedanib, and Ripretinib) were purchased from MedChemExpress, dissolved in DMSO to a 10 mM stock, and stored at −80°C.

Techniques: In Vivo, Expressing